АДЕНОЗИН КАК ПОТЕНЦИАЛЬНАЯ МИШЕНЬ ДЛЯ БИОТЕРАПИИ РАКА
В данном обзоре литературы расссматривается роль внеклеточного аденозина в формировании иммуносупрессивного аденозинергического микроокружения солидных опухолей. Вызванное гипоксией накопление внеклеточного аденозина в концентрации 50– 100 мкМ (норма 10–100 нМ) является патофизиологическим признаком широкого круга злокачественных новообразований у человека. У аденозина как сигнальной молекулы выявлено четыре типа поверхностно-клеточных рецепторов, активация которых приводит к ингибированию эффекторных функций цитотоксических Т-лимфоцитов, натуральных киллеров и макрофагов, играющих ключевую роль в противоопухолевых иммунных ответах. Автором предложена идея устранения защиты рака от иммунитета с помощью денозиндезаминазы, слитой с аннексином-А5. По мнению автора, такой химерный белок при введении в организм пациентов, страдающих от онкологических заболеваний, будет связываться только с раковыми клетками и разрушать аденозин, защищающий эти клетки от противоопухолевого иммунитета.
1. Blay, J. Adenosine and tumor microenvironment / J. Blay // Encyclopedia of Cancer. – 3rd ed. – Heidelberg: Springer, 2012. – P. 49–53.
2. How systemic inflammation modulates adenosine metabolism and adenosine receptor expression in humans in vivo / B. P. Ramakers [et al.] // Crit. Care. Med. – 2012. – Vol. 40, N 9. – P. 2609–2616.
3. Spychala, J. Tumor-promoting functions of adenosine / J. Spychala // Pharmacol. Ther. – 2000. – Vol. 87, N 2–3. – P. 161–173.
4. Volmer, J. B. Ecto-5′-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin- induced lung injury / J. B. Volmer, L. F. Thompson, M. R. Blackburn // J. Immunol. – 2006. – Vol. 176. – P. 4449–4458.
5. Lack of effect of extracellular adenosine generation and signaling on renal erythropoietin secretion during hypoxia / A. Grenz [et al.] // Am. J. Physiol. Renal Physiol. – 2007. – Vol. 293. – P. 1501–1511.
6. The equilibrative nucleoside transporter family, SLC29 / S. A. Baldwin [et al.] // Pflugers Arch. – 2004. – Vol. 447, N 5. – P. 735–743.
7. Busse, M. Accumulation of purine catabolites in solid tumors exposed to therapeutic hyperthermia / M. Busse, P. Vaupel // Experientia. – 1996. – Vol. 52, N 5. – P. 469–473.
8. Hasko, G. Adenosine: an endogenous regulator of innate immunity / G. Hasko, B. N. Cronstein // Trends Immunol. – 2004. – Vol. 25, N 1. – P. 33–39.
9. A2A adenosine receptor protects tumors from antitumor T cells / A. Ohta [et al.] // Proc. Natl. Acad. Sci. USA. – 2006. – Vol. 103. – P. 13132–13137.
10. Vaupel, P. Hypoxia-driven adenosine accumulation: a crucial microenvironmental factor promoting tumor progression / P. Vaupel, A. Mayer // Adv. Exp. Med. Biol. – 2016. – Vol. 876. – P. 177–183.
11. Kobayashi, S. Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport / S. Kobayashi, H. Zimmermann, D. E. Millhorn // J. Neurochem. – 2000. – Vol. 74. – P. 621–632.
12. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia / K. Synnestvedt [et al.] // J. Clin. Invest. – 2002. – Vol. 110. – P. 993–1002.
13. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release / U. K. Decking [et al.] // Circ. Res. – 1997. – Vol. 81. – P. 154–164.
14. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors / B. B. Fredholm [et al.] // Pharmacol. Rev. – 2001. – Vol. 53. – P. 527–552.
15. Linden, J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection / J. Linden // Annu. Rev. Pharmacol. Toxicol. – 2001. – Vol. 41. – P. 775– 787.
16. The A2aR adenosine receptor controls cytokine production in iNKT cells / M. Nowak [et al.] // Eur. J. Immunol. – 2010. – Vol. 40, N 3. – P. 682–687.
17. Vaupel, P. Adenosine can thwart antitumor immune responses elicited by radiotherapy. Therapeutic strategies alleviating protumor ADO activities / P. Vaupel, G. Multhoff // Strahlender Onkol. – 2016. – Vol. 192, N 5. – P. 279–287.
18. Ohta, A. A metabolic immune checkpoint: adenosine in tumor microenvironment / A. Ohta // Front. Immunol. – 2016. – Vol. 7: 109. doi: 10.3389/fimmu.2016.00109.
19. Hasko, G. Regulation of macrophage function by adenosine / G. Hasko, P. Pacher // Arterioscler. Thromb. Vasc. Biol. – 2012. – Vol. 32. – P. 865–869.
20. Myeloid cells in the tumor microenvironment: role of adenosine / S. Morello [et al.] // Oncoimmunology. – 2016. – Vol. 5, N 3: e1108515.
21. Itoh, K. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas / K. Itoh, A. B. Tilden, C. M. Balch // Cancer Res. – 1986. – Vol. 46. – P. 3011–3017.
22. Immunity, inflammation and cancer: a leading role for adenosine / L. Antonioli [et al.] // Nat. Rev. Cancer. – 2013. – Vol. 13, N 12. – P. 842–857.
23. Staphylococcus aureus synthesizes adenosine to escape host immune responses / V. Thammavongsa [et al.] // J. Exp. Med. – 2009. – Vol. 206. – P. 2417–2427.
24. Release of ATP during host cell killing by enteropathogenic E. coli and its role as a secretory mediator / J. K. Crane [et al.] // Am. J. Physiol. Gastrointest. Liver Physiol. – 2002. – Vol. 283. – P. G74–G86.
25. Characterization of an ecto-5′-nucleotidase (EC 3.1.3.5) activity in intact cells of Trichomonas vaginalis / T. Tasca [et al.] // Exp. Parasitol. – 2003. – Vol. 105. – P. 167–173.
26. Targeting cancer-derived adenosine: new therapeutic approaches / A. Young [et al.] // Cancer Discov. – 2014. – Vol. 4, N 8. – P. 879–888.
27. Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists / M. V. Sitkovsky [et al.] // Cancer Immunol. Res. – 2014. – Vol. 2, N 7. – P. 598–605.
28. Ohta, A. Extracellular adenosine-mediated modulation of regulatory T cells / A. Ohta, M. Sitkovsky // Front. Immunol. – 2014. – Vol. 5: 304. doi: 10.3389/fimmu.2014.00304.
29. Adenosine pathway and cancer: where to go from here? / L. Antonioli [et al.] // Expert Opin. Ther. Targets. – 2014. – Vol. 18, N 9. – P. 973–977.
30. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine- dependent immune evasion / S. F. Hausler [et al.] // Am. J. Transl. Res. – 2014. – Vol. 6, N 2. – P. 129–139.
31. A glance at adenosine receptors: novel target for antitumor therapy / S. Merighi [et al.] // Pharmacol. Ther. – 2003. – Vol. 100, N 1. – P. 31–48.
32. Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells / M. Sitkovsky [et al.] // Br. J. Pharmacol. – 2008. – Vol. 153, suppl. 1. – P. S457–S464.
33. Immunological mechanisms of the antitumor effects of supplemental oxygenation / S. M. Hatfield [et al.] // Sci. Transl. Med. – 2015. – Vol. 7, N 277: 277ra230. doi: 10.1126/scitranslmed.aaa1260.
34. Hatfield, S. M. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1a driven immunosuppression and improve immunotherapies of cancer / S. M. Hatfield, M. Sitkovsky // Curr. Opin. Pharmacol. – 2016. – Vol. 29, N 1. – P. 90–96.
35. Hatfield, S. M. Oxygenation to improve cancer vaccines, adoptive cell transfer and blockade of immunological negative regulators / S. M. Hatfield, M. Sitkovsky // Oncoimmunology. – 2015. – Vol. 4, N 12: e1052934. doi: 10.1080/ 2162402X.2015.1052934. 36. Adenosine receptors: expression, function and regulation / S. Sheth [et al.] // Int. J. Mol. Sci. – 2014. – Vol. 15, N 2. – P. 2024–2052.
36. Cekic, C. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment / C. Cekic, J. Linden // Cancer Res. – 2014. – Vol. 74. – P. 7239–7249.
37. Targeting CD73 enhances the anti-tumor activity of anti-PD-1 and anti-CTLA-4 mAbs / B. Allard [et al.] // Clin. Cancer Res. – 2013. – Vol. 19. – P. 5626–5635.
38. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses / P. A. Beavis [et al.] // Cancer Immunol. Res. – 2015. – Vol. 3. – P. 506–517.
39. Immunosuppressive activities of adenosine in cancer / B. Allard [et al.] // Curr. Opin. Pharmacol. – 2016. – Vol. 29. – P. 7–16.
40. Cellular and humoral immunity to different types of human neoplasms / I. Hellstrom [et al.] // Nature. – 1968. – Vol. 220. – P. 1352–1354.
41. Lukashev, D. From “Hellstrom Paradox” to anti-adenosinergic cancer immunotherapy / D. Lukashev, M. Sitkovsky, A. Ohta // Purin. Sign. – 2007. – Vol. 3. – P. 129–134.
42. Malhotra, V. Classical chemotherapy: mechanisms, toxicities and the therapeutic window / V. Malhotra, M. C. Perry // Cancer Biol. Ther. – 2003. – Vol. 2, suppl. 1. – P. S2–S4. 44. Corrie, P. G. Cytotoxic chemotherapy: clinical aspects / P. G. Corrie // Medicine. – 2011. – Vol. 39. – P. 717–722.
43. Immune evasion in cancer: mechanistic basis and therapeuticstrategies / D. S. Vinay [et al.] // Semin. Cancer Biol. – 2015. – Vol. 35, suppl. – P. S185–S198. doi: 10.1016/j.semcancer.2015.03.004.
44. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human bloodmonocytes / T. Utsugi [et al.] // Cancer Res. – 1991. – Vol. 51. – P. 3062–3066.
45. Ran, S. Increased exposure of anionic phospholipids on the surface of tumor blood vessels / S. Ran, A. Downes, P. E. Thorpe // Cancer Res. – 2002. – Vol. 62, N 21. – P. 6132– 6140.
46. Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer / R. B. Birge [et al.] // Cell Death Differ. – 2016. – Vol. 23, N 6. – P. 962– 978.
47. Zwaal, R. F. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells / R. F. Zwaal, A. J. Schroit // Blood. – 1997. – Vol. 89. – P. 1121–1132.
48. Regulatory mechanisms of transmembrane phospholipid distributions and pathophysiological implications of transbilayer lipid scrambling / E. M. Bevers [et al.] // Lupus. – 1998. – Vol. 7, suppl. 2. – P. 126–131.
49. Variation in human cancer cell external phosphatidylserine is regulated by flippase activity and intracellular calcium / S. D. Vallabhapurapu [et al.] // Oncotarget. – 2015. – Vol. 6, N 33. – P. 34375–34388.
50. A review of stimuli-responsive nanocarriers for drug and gene delivery / S. Ganta [et al.] // J. Control. Release. – 2008. – Vol. 126, N 3. – P. 187–204.
51. In search of new targets – the membrane lipid phosphatidylserine – the underestimated Achilles’ Heel of cancer cells / D. Zweytick [et al.] // Ann. Oncol. – 2011. – Vol. 22, Suppl. 3. – P. 43.
52. Schick, P. K. Location of phosphatidylethanolamine and phosphatidylserine in the human platelet plasma membrane / P. K. Schick, K. B. Kurica, G. K. Chacko // J. Clin. Invest. – 1976. – Vol. 57. – P. 1221–1226.
53. Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers / H. A. Andree [et al.] // J. Biol. Chem. – 1990. – Vol. 265. – P. 4923–4928.
54. Krais, J. J. Purine nucleoside phosphorylase targeted by Annexin V to breast cancer vasculature for enzyme prodrug therapy / J. J. Krais, O. De Crescenzo, R. G. Harrison // PLoS ONE. – 2013. – Vol. 8, N 10: e76403.57. Application of recombinant enzymes for the synthesis of pharmaceutically valuable nucleosides and nucleotides / D. V. Burko [et al.] // Biotechnology in Medicine, Foodstuffs, Biocatalysis, Environment and Biogeotechnology / eds: S. D. Varfolomeev, G. E. Zaikov, L. P. Krylova. – New York: Nova Science Publishers, Inc., 2010. – Р. 1–13.
55. Enzymatic synthesis of c-di-GMP using inclusion bodies of Thermotoga maritima full-length diguanylate cyclase / A. S. Korovashkina [et al.] // J. Biotechnol. – 2013. – Vol. 164, N 2. – P. 276–280.
56. Рымко, А. Н. Создание штамма Escherichia coli, продуцирующего дезоксинуклеозидкиназу Drosophila melanogaster / А. Н. Рымко, С. В. Квач, А. И. Зинченко // Вес. Нац. акад. навук Беларусi. Сер. бiял. навук. – 2013. – № 2. – С. 87–90.
57. Мишура, А. А. Создание штаммов-продуцентов химерых белков, содержащих в своей структуре хитинсвязывающий домен / А. А. Мишура, А. Н., Рымко, А. И. Зинченко // Сахаровские чтения 2016 г.: экол. проблемы XXI века: материалы 15-й междунар. науч. конф., Минск, 19–20 мая 2016 г. / МГЭИ им. А.Д. Сахарова БГУ. – С. 85.
58. Квач, С. В. Оптимизация условий экспрессии штамма-суперпродуцента аденозиндезаминазы Escherichia coli / С. В. Квач, Л. А. Ерошевская, А. И. Зинченко // Динамика изследования – 2008: материали за IV Междунар. науч.-практ. конф., София, 16–31 юли 2008 г. – Т. 22. – С. 26–29.
59. Ерошевская, Л. А. Получение и использование генноинженерной аденозиндезаминазы Escherichia coli / Л. А. Ерошевская, С. В. Квач, А. И. Зинченко // Совр. пробл. физиол., экол. и биотехнол. микроорганизмов: материалы Всерос. симп. с междунар. участием. М., МГУ, 24–27 дек. 2009 г. – С. 61.
60. Синтез пуриновых 3ʹ-α-фторнуклеозидов с использованием пиримидиннуклеозидфосфорилазы Thermus thermophilus и пуриннуклеозидфосфорилазы Escherichia coli / А. И. Береснев [и др.] // Вес. Нац. акад. навук Беларусi. Сер. бiял. навук. – 2013. – № 4. – С. 71–76.